Adverse Effects of ACE Inhibitors in Geriatric Patients

Introduction to Adverse Effects

The European Society of Cardiology recommends that ACE inhibitors be used with caution in elderly patients due to the risk of hypotension, hyperkalemia, renal dysfunction, dry cough, and angioedema 1

First-dose hypotension is a critical concern when initiating ACE inhibitors in elderly patients, particularly those on diuretics, with heart failure, or who are volume-depleted 1
Orthostatic hypotension occurs more frequently in the elderly due to impaired cardiovascular reflexes and decreased baroreceptor response that accompanies aging 1
ACE inhibitors can cause acute deterioration of renal function, particularly in elderly patients with pre-existing chronic kidney disease, volume depletion, or bilateral renal artery stenosis 1
Potassium retention is a significant risk, especially when ACE inhibitors are combined with potassium-sparing diuretics, potassium supplements, or NSAIDs 1
Dry, persistent cough occurs in a subset of patients and is a class effect of all ACE inhibitors 1

The American Heart Association recommends starting with the lowest effective dose due to altered pharmacokinetics and pharmacodynamics in elderly patients 1, 2
Measure both supine and standing blood pressure before and after initiation to detect orthostatic changes 1, 2
Calculate creatinine clearance before starting therapy, as most ACE inhibitors are renally excreted and accumulate in renal impairment 1, 2
Titrate slowly with prolonged periods between dose adjustments, as elderly patients are more susceptible to adverse effects 2
Monitor blood pressure regularly, checking both supine and standing measurements 1, 2
Assess renal function and serum potassium within 1-2 weeks of initiation and with each dose increase 1, 2

The European Society of Cardiology recommends checking both supine and standing blood pressure to identify orthostatic dysregulation in elderly patients, which is particularly problematic in this population 3, 4
The American Geriatrics Society suggests monitoring renal function within 1-2 weeks of initiation and with each dose increase, as well as checking serum potassium levels within 1-2 weeks, as hyperkalemia risk is highest early in therapy 5
The European Society of Cardiology advises ongoing monitoring of blood pressure for adequate control in elderly patients 3, 6

The European Society of Cardiology recommends introducing Physiotens even more cautiously with lower doses and preferably under supervision in heart failure patients, and may need to temporarily stop diuretics to prevent severe hypotension 4
The American Geriatrics Society suggests that ACE inhibitors, such as Physiotens, are particularly beneficial for preventing diabetic nephropathy progression in diabetic patients, and recommends targeting blood pressure <140/80 mmHg (or <130/80 for additional benefit) 5

The European Society of Cardiology advises avoiding or using extreme caution in patients with creatinine clearance <30 mL/min, and dose reduction is mandatory; avoid if <10 mL/min 4